Scientific exchange · Dr. Benedikt Xu

31 Jul 2026 · Phone · Dr. Benedikt Xu, Universitätsklinikum Heidelberg · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0157—

Capture insight from this engagement

Location: Universitätsklinikum Heidelberg
Therapeutic area: Nephrology
Country: Germany
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Proteinuria as surrogate endpoint
APRIL pathway mechanism

Scientific content used

NPH mechanism-of-action deck
Surrogate-endpoint evidence review

Questions raised

What is the immunoglobulin monitoring recommendation?

Notes

Scientific exchange with academic nephrologist at Universitätsklinikum Heidelberg. Discussed proteinuria as surrogate endpoint, april pathway mechanism.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 3
Depth of exchange: 2
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0157

Audit history (0)

All create, update and approval events for this record

No audit events in sample data